JP2016512505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512505A5 JP2016512505A5 JP2016500933A JP2016500933A JP2016512505A5 JP 2016512505 A5 JP2016512505 A5 JP 2016512505A5 JP 2016500933 A JP2016500933 A JP 2016500933A JP 2016500933 A JP2016500933 A JP 2016500933A JP 2016512505 A5 JP2016512505 A5 JP 2016512505A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- substituted
- phenyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 64
- 125000001072 heteroaryl group Chemical group 0.000 claims 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 25
- 125000000623 heterocyclic group Chemical group 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 3
- -1 —NH—C 3-6 cycloalkyl Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775731P | 2013-03-11 | 2013-03-11 | |
| US61/775,731 | 2013-03-11 | ||
| US14/200,055 | 2014-03-07 | ||
| US14/200,055 US9050345B2 (en) | 2013-03-11 | 2014-03-07 | Pyrrolotriazines as potassium ion channel inhibitors |
| PCT/US2014/022265 WO2014143610A1 (en) | 2013-03-11 | 2014-03-10 | Pyrrolotriazines as potassium ion channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512505A JP2016512505A (ja) | 2016-04-28 |
| JP2016512505A5 true JP2016512505A5 (enExample) | 2017-04-13 |
| JP6427551B2 JP6427551B2 (ja) | 2018-11-21 |
Family
ID=51488539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500933A Expired - Fee Related JP6427551B2 (ja) | 2013-03-11 | 2014-03-10 | カリウムイオンチャネル阻害剤としてのピロロトリアジン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9050345B2 (enExample) |
| EP (1) | EP2970296B1 (enExample) |
| JP (1) | JP6427551B2 (enExample) |
| CN (1) | CN105008367B (enExample) |
| AR (1) | AR095208A1 (enExample) |
| TW (1) | TW201444847A (enExample) |
| UY (1) | UY35381A (enExample) |
| WO (1) | WO2014143610A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2858987T (pt) * | 2012-06-11 | 2018-07-04 | Bristol Myers Squibb Co | Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin -2-il]piridina-3-sulfonamida |
| JP6395798B2 (ja) * | 2013-03-11 | 2018-09-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カリウムイオンチャネル阻害剤としてのピロロトリアジン |
| ES2616026T3 (es) | 2013-03-11 | 2017-06-09 | Bristol-Myers Squibb Company | Pirrolopiridazinas como inhibidores de canales de iones potasio |
| WO2014143609A1 (en) | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
| WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN107922422A (zh) * | 2015-08-31 | 2018-04-17 | 百时美施贵宝公司 | TGFβ受体拮抗剂 |
| CN105111154A (zh) * | 2015-09-15 | 2015-12-02 | 上海瑞博化学有限公司 | 一种5-氨基吡嗪-2-甲酸合成新工艺 |
| EP3394056B1 (en) | 2015-12-22 | 2021-04-14 | Shy Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| AU2017241524B2 (en) | 2016-03-28 | 2021-07-08 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
| EA039529B1 (ru) | 2016-04-28 | 2022-02-07 | Такеда Фармасьютикал Компани Лимитед | Конденсированные гетероциклические соединения |
| US11382881B2 (en) | 2017-05-05 | 2022-07-12 | Nino Sorgente | Methods and compositions for diagnosing and treating glaucoma |
| CA3062170A1 (en) | 2017-05-05 | 2018-11-08 | Nino Sorgente | Methods and compositions for improving eye health |
| CA3066939A1 (en) | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN111825675B (zh) * | 2019-04-15 | 2023-08-01 | 武汉朗来科技发展有限公司 | Rock抑制剂及其制备方法和用途 |
| EP4244213A4 (en) * | 2020-11-10 | 2024-11-20 | Foghorn Therapeutics Inc. | COMPOUNDS AND USES THEREOF |
| JP2025512935A (ja) | 2022-04-08 | 2025-04-22 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリータンパク質と相互作用する化合物 |
| CA3252955A1 (en) | 2022-05-11 | 2023-11-16 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| CN116063183B (zh) * | 2023-01-28 | 2023-06-27 | 山东国邦药业有限公司 | 一种环丙胺的合成方法 |
| WO2025077671A1 (zh) * | 2023-10-09 | 2025-04-17 | 浙江海正药业股份有限公司 | 多取代芳基类衍生物及其制备方法和用途 |
| WO2026019945A1 (en) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ATE416772T1 (de) | 1998-07-06 | 2008-12-15 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
| ES2258459T3 (es) | 1999-05-21 | 2006-09-01 | Bristol-Myers Squibb Company | Pirrolotriazinas inhibidoras de quinasas. |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| DK1363910T3 (da) | 2000-11-17 | 2006-06-26 | Bristol Myers Squibb Co | Fremgangsmåder til behandling af P39-kinase-associerede tilstande og pyrrolotriazinforbindelser, der er anvendelige som kinase-inhibitorer |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US6951859B2 (en) | 2002-08-02 | 2005-10-04 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| BRPI0407282A (pt) | 2003-02-05 | 2006-01-31 | Bristol Myers Squibb Co | Processo para preparação de inibidores de pirrolotriazina cinase |
| US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| JP5046942B2 (ja) | 2004-09-30 | 2012-10-10 | テイボテク・フアーマシユーチカルズ | Ｈｃｖ阻害性の二環式ピリミジン類 |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2007223342A1 (en) | 2006-03-07 | 2007-09-13 | Bristol-Myers Squibb Company | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
| WO2007107005A1 (en) | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
| WO2008005956A2 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| CN101687874B (zh) | 2007-04-18 | 2013-01-30 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| BRPI0815503A2 (pt) | 2007-08-17 | 2014-09-30 | Icagen Inc | Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico |
| DE102007051762A1 (de) * | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
| CN102015719A (zh) | 2008-03-06 | 2011-04-13 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| US20110269740A1 (en) | 2008-07-02 | 2011-11-03 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| CN102245610B (zh) * | 2008-10-08 | 2014-04-30 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| EP3575288B1 (en) * | 2009-09-03 | 2021-10-27 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
| PT2858987T (pt) * | 2012-06-11 | 2018-07-04 | Bristol Myers Squibb Co | Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin -2-il]piridina-3-sulfonamida |
-
2014
- 2014-03-07 US US14/200,055 patent/US9050345B2/en active Active
- 2014-03-10 WO PCT/US2014/022265 patent/WO2014143610A1/en not_active Ceased
- 2014-03-10 TW TW103108204A patent/TW201444847A/zh unknown
- 2014-03-10 EP EP14713005.8A patent/EP2970296B1/en not_active Not-in-force
- 2014-03-10 AR ARP140100817A patent/AR095208A1/es unknown
- 2014-03-10 JP JP2016500933A patent/JP6427551B2/ja not_active Expired - Fee Related
- 2014-03-10 CN CN201480013619.4A patent/CN105008367B/zh not_active Expired - Fee Related
- 2014-03-11 UY UY0001035381A patent/UY35381A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512505A5 (enExample) | ||
| JP2016514129A5 (enExample) | ||
| JP2016512504A5 (enExample) | ||
| JP2016516691A5 (enExample) | ||
| JP2014015465A5 (enExample) | ||
| JP2016006118A5 (enExample) | ||
| JP2015508749A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| JP2016534134A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2013537203A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2016505512A5 (enExample) | ||
| JP2015512931A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2020527175A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2016528273A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2016515560A5 (enExample) | ||
| RU2016137678A (ru) | Соединения с эфирными группами для лечения опосредованных комплементом нарушений | |
| JP2017514855A5 (enExample) | ||
| RU2016115487A (ru) | Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda |